Compounded GLP-1 Legal Status in 2026
This is the single most important thing to understand before buying a compounded GLP-1, and it is the thing most comparison sites have not updated. The regulatory ground under compounded semaglutide and tirzepatide has shifted substantially, and it is still moving.
The short version
The FDA declared the semaglutide shortage resolved in February 2025. That removed the legal basis for mass-market compounding of copies, and the deadlines for pharmacies to stop passed in 2025. In April 2026 the FDA went further and proposed to permanently exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk drug substance.
Compounded GLP-1s have not vanished — but the basis on which they are supplied has narrowed, and it is now a genuinely reasonable question to ask any provider directly.
How we got here
- February 21, 2025
Semaglutide shortage declared resolved
The FDA issued a declaratory order determining that the shortage of semaglutide injection products was resolved. Once a drug is no longer in shortage, compounded copies are generally no longer permitted.
- March 2025
Tirzepatide compounding discretion ends
The FDA ended enforcement discretion for compounded tirzepatide, with outsourcing facilities required to stop by March 19, 2025.
- April 22, 2025
503A deadline for semaglutide
State-licensed 503A compounding pharmacies were required to stop compounding semaglutide injection products.
- May 22, 2025
503B deadline for semaglutide
503B outsourcing facilities were required to stop compounding semaglutide injection products.
- September 2025 – April 2026
FDA warning letters issued
The FDA issued warning letters to compounders including GLP-1 Solution and ProRx LLC, stating that drug products compounded using tirzepatide bulk drug substance are not eligible for the exemptions provided by section 503B.
- March 3, 2026
FDA warns 30 telehealth companies
The FDA issued 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products, citing marketing that falsely suggests compounded GLP-1s are identical to FDA-approved products and misrepresents sourcing.
- April 1, 2026
FDA reminder to compounders
The FDA reminded compounders that certain conditions must be met for compounded drugs to qualify for the exemptions under sections 503A and 503B.
- April 30, 2026
FDA proposes permanent exclusion
The FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk drug substance.
- May 1, 2026
Federal Register notice published
A notice titled "List of Bulk Drug Substances for Which There Is a Clinical Need" identified the three substances the FDA proposes not to include on the 503B bulks list.
Why compounded GLP-1s still exist
If mass-market compounding of copies is no longer permitted, why can you still buy compounded semaglutide from dozens of telehealth platforms? The answer sits in the difference between copying an approved drug and compounding for an individual clinical need.
Compounding law has always allowed a licensed pharmacy to prepare a medication for an individual patient when a prescriber documents that the approved product does not meet that patient's needs — a different strength than any commercially available dose, for example, or a formulation avoiding an inactive ingredient the patient reacts to. That is the mechanism most remaining compounded GLP-1 offerings now rely on, and it is why you see so much marketing language about "personalized" and "customized" dosing.
Whether every program operating on that basis is doing so legitimately is a question regulators are actively working through. The FDA's warning letters to compounders, and its April 2026 reminder that specific conditions must be met to qualify for the 503A and 503B exemptions, indicate it does not consider the matter settled.
What this means for the 503B claim. Several telehealth platforms market their medication as coming from FDA-registered 503B outsourcing facilities, and historically that was a genuine quality signal. Given the proposed exclusion of these three molecules from the 503B bulks list, that claim now deserves a direct question rather than assumed reassurance: ask on what basis your specific prescription is being compounded.
What providers have actually done
Watching how companies responded is more informative than reading their marketing. Across the providers we review, three distinct positions emerged.
- Withdrew entirely
- Sesame states compounded semaglutide is not currently available through its platform, noting compounded semaglutide products are no longer permitted under current regulations. QuickMD states compounded semaglutide is no longer available due to FDA regulations.
- Never offered it
- Form Health states directly that it does not prescribe compounded medication, and Klinic states it does not prescribe compounded semaglutide, compounded tirzepatide or any other compounded weight-loss medication.
- Continued, with disclosure
- Many platforms continue to offer compounded GLP-1s while stating clearly that the product is not FDA-approved. Revibe Men's Health and Trimi both publish that disclosure prominently.
None of these positions is automatically right or wrong. But a company that quietly kept selling while removing the disclosure is telling you something different from one that kept selling and kept the disclosure visible.
What changed on the price side
The regulatory tightening coincided with something that removes much of the original argument for compounding: the manufacturers cut their own prices dramatically.
NovoCare Pharmacy now sells FDA-approved Wegovy and Ozempic direct from $149 a month for the pill and $199 for the pen. LillyDirect sells Zepbound from $299 to a flat $449. Compounded programs run roughly $70 to $545 a month depending on molecule, dose and membership fees.
In other words, the gap that made compounding compelling in 2023 has largely closed. For many patients the approved product is now comparable in price and unambiguous in status. Our cost guide works through the arithmetic.
Questions worth asking your provider
- On what basis is my prescription being compounded, given the shortage has ended?
- Is the pharmacy a 503A or a 503B facility, and can you name it?
- Is my formulation a different strength or composition from the approved product, and why?
- What happens to my subscription if the FDA finalizes the proposed exclusion?
- Would an FDA-approved product at $149–$449 a month be appropriate for me instead?
A provider that answers these plainly is one worth staying with. See our guide to vetting a GLP-1 provider.
Frequently asked questions
Am I doing something illegal by buying compounded semaglutide?
Compounding regulation governs pharmacies and prescribers, not patients. The practical risk to you is not legal exposure — it is that you may be taking a product the FDA has not reviewed for safety, effectiveness or quality, from a supply chain that is under active regulatory pressure and may not be there next quarter.
Will compounded GLP-1s disappear completely?
Unclear. The April 2026 proposal is a proposal, not a final rule, and compounding for documented individual clinical need is a long-standing part of pharmacy practice that these actions do not eliminate. But the direction of travel is consistent, and planning around continued cheap access would be optimistic.
Should I switch to a brand-name product?
That is a clinical and financial decision for you and your prescriber, but the case is stronger than it was. Approved semaglutide now starts at $149/mo direct and approved tirzepatide at $299/mo, both with no ambiguity about what is in the vial. See compounded vs. brand-name.
What about compounded products with B12 or glycine added?
Added ingredients are often presented as a clinical rationale for compounding. Note that Eli Lilly has warned it found significant levels of an impurity in certain compounded tirzepatide products containing vitamin B12, and published analysis has questioned the justification for adding nutrients to these preparations. Ask your prescriber why any additive is in your specific formulation.
Primary sources
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide on 503B Bulks List
- Federal Register — List of Bulk Drug Substances for Which There Is a Clinical Need (May 1, 2026)
- FDA — Clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA — Declaratory Order: Resolution of Shortages of Semaglutide Injection
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA — Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
- FDA — Telehealth companies: what to know when promoting compounded drugs
- FDA — Human Drug Compounding Policies and Rules
- FDA warning letter — ProRx LLC (April 7, 2026)
- Stanford Medicine — Compounded GLP-1s: why doctors worry and the FDA is cracking down
Where to go next
Disclaimer
This article is general information, not legal or medical advice. It summarizes publicly available FDA and Federal Register material as of August 3, 2026; regulatory positions change and a proposal is not a final rule. Verify current status with the FDA directly and discuss your own treatment with a licensed healthcare professional. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality.
Date reviewed: August 3, 2026